January 18, 2023
A Pennsylvania federal judge on Wednesday approved a $44 million deal between biotechnology firm Inovio Pharmaceuticals Inc. and its investors to resolve claims that the company's alleged misrepresentation of its COVID-19 vaccine development efforts in early 2020 prompted its stock price to plunge.
August 23, 2022
Biotechnology firm Inovio Pharmaceuticals Inc. has reached a $44 million settlement agreement with its investors, which if approved would end claims that the company's misrepresentation of its COVID-19 vaccine development efforts in early 2020 prompted its stock price to plunge.
January 24, 2022
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives doubled down on their arguments to a Pennsylvania federal court Friday and urged against class certification for investors bringing claims over the executives' statements on a coronavirus vaccine.
July 30, 2021
A class of investors moved for certification Thursday in their suit against biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives alleging that they misled the public about a coronavirus vaccine they purported to have in the works.
February 16, 2021
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives must face slightly trimmed class action claims alleging they misled the public about a coronavirus vaccine they purport to have in the works, a Pennsylvania federal judge ruled Tuesday.
December 22, 2020
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives shouldn't be allowed to shake off a consolidated class action alleging they misled the public about a coronavirus vaccine they purport to have in the works, Inovio shareholders told a federal court in Philadelphia.
November 05, 2020
Inovio Pharmaceuticals Inc. said Thursday that it has been entirely upfront with investors about its efforts to develop and produce a COVID-19 vaccine, contrary to the claims of a securities suit it wants dismissed.
June 19, 2020
Robbins Geller Rudman & Dowd LLP, with an assist from Saxton & Stump, will represent a proposed class of shareholders in a suit alleging Inovio Pharmaceuticals Inc. inflated its stock price by confusing the public with claims about a "three-hour" development timeline for a COVID-19 vaccine.
May 29, 2020
At least 50 federal securities cases with references to COVID-19 have been filed in the past three months, including merger challenges, regulatory enforcement actions and sprawling investor suits, according to a Law360 review of filings. As the pandemic pushes into the summer, Law360 is taking a look at eight major investor actions that were brought in connection with the novel coronavirus since March.
May 13, 2020
Nine law firms including Block & Leviton LLP and The Rosen Law Firm PA are competing to be lead counsel in a proposed stock drop class action against Inovio Pharmaceuticals, where investors allege the biotech company's statements it was ready to test a COVID-19 vaccine inflated the stock price before the company walked the statements back.